

- ⁶ 22 ⁶ Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; 23 Guangzhou, 510120, China.
- ⁷ 24 ⁷ Department of Cellular & Molecular Diagnostics Center, Sun Yat-Sen Memorial Hospital,
- 25 Sun Yat-Sen University; Guangzhou, 510120, China.
- ⁸ Department of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA, 02215, USA.
- ⁹ 3 School of Dentistry, Shenzhen University Medical School; Shenzhen, 518037, China.
- 10 10 $\frac{10}{1}$ $\$ 29 College, Nanchang University; Nanchang, 330008, China.
- ¹¹ Clinical Research Design Division, Clinical Research Center, Sun Yat-sen Memorial 31 Hospital, Sun Yat-sen University; Guangzhou, 510120, China.
- ¹² Lecturer, Department of Gastroenterological Surgery, Faculty of Medicine, Fukuoka 33 University; Fukuoka, 814-0180, Japan.
- ¹³ 1³ Institute of Hepatopancreatobiliary Surgery, Chongqing General Hospital, Chongqing 35 University; Chongqing, 400038, China.
- 14 Cancer Institute, Xuzhou Medical University; Xuzhou, 221004, China.
- ¹⁵ Department of Surgery, Massachusetts General Hospital, Harvard Medical School; Boston, 38 02115, USA.
- ¹⁶ Faculty of Life and Health Sciences, Shenzhen University of Advanced Technology; 40 Shenzhen, 518107, China.
- ¹⁷ 41 Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced 42 Technology, Chinese Academy of Sciences; Shenzhen, 518055, China.

53

Abstract: Recent advancements in cancer immunotherapy have improved patient outcomes, yet responses to immunotherapy remain moderate. We conducted a Phase II clinical trial (NCT04718415) involving 51 cancer patients undergoing neoadjuvant chemoimmunotherapy and applied single-cell RNA and T/BCR sequencing on tumor and blood samples to elucidate the immune cell perturbations. Our findings associate poor response with reduced levels of CCR7⁺CD4 Naïve T cells and CD27⁺ Memory B cells, as well as higher expression of immunosenescence-related genes in T and B cell subsets. Using naturally aged and $Erc1^{+/}$ **transgenic aging mouse models, we found that senolytics enhance the therapeutic efficacy of immunotherapy in multiple solid tumors by mitigating tumor immunosenescence. Notably, we launched a Phase II clinical trial, COIS-01 (NCT05724329), which pioneers the combination of senolytics with anti-PD-1 therapy. The**

clinical results demonstrate that this therapeutic strategy is associated with a favorable safety profile and therapeutic efficacy, significantly mitigating adverse effects and alleviating immunosenescence. These findings underscore the pivotal role of immunosenescence characteristics in influencing the effectiveness of immunotherapy and suggest a promising therapeutic efficacy along with a beneficial safety assessment for the combination of senolytics with anti-PD-1 therapy.

71 **Main Text:**

72 Despite recent advancements in blocking the PD-1/PD-L1 pathway, which have 73 revolutionized the treatment of solid tumors, only a small fraction of patients benefits from $\frac{1}{3}$ immunotherapy, with fewer than 20% showing sustained responses $\frac{1}{3}$. A major challenge in 75 current immunotherapy and neoadjuvant strategies is our limited understanding of the highly 76 dynamic and heterogeneous tumor immune microenvironment (TIME), which impacts treatment responses $4-6$. The concept of cancer immunoediting emphasizes the immune system's dual role 78 in inhibiting tumor growth and shaping tumor immunogenicity. This process is described in three 79 stages: elimination, equilibrium, and escape. During the elimination phase, the host's innate and adaptive immune systems recognize and respond to tumor-specific antigens 7.8 . T cells are the 81 primary players in tumor immunity. Although tumor-reactive T cells are present in TIME, the 82 phenotypic heterogeneity of T cells across different tumors and their divergent differentiation 83 fates remain significant. Exhaustion still poses a major limitation to their anti-tumor potential 84 9,10

85 Immunosenescence, a well-established phenomenon occurring with age, results in the $\frac{11-15}{11-15}$ immune system losing its ability to effectively respond to pathogens and cancer cells $\frac{11-15}{11-15}$. 87 Recent studies have uncovered the complex role of immunosenescence in tumors, with factors

88 such as cAMP, glucose competition, and oncogenic stress in the TIME inducing senescence in T 89 cells, macrophages, natural killer (NK) cells, and dendritic cells, thereby impairing their immune 90 . cytotoxic function against tumors 16 . However, it remains unclear whether individual differences 91 in immunosenescence affect the efficacy of immunotherapy in cancer patients.

92 Previous studies have shown that blocking DNA damage signals can inhibit the senescence of 93 tumor-infiltrating T cells, thereby enhancing the efficacy of immune checkpoint inhibitors (ICIs) against tumors 17 . Recent research also indicate that chronic inflammation caused by an aging 95 immune system can promote cancer development, regardless of the age of the cancerous or 96 surrounding tissues 18 . Therefore, we believe that the senescence status of immune cell 97 subpopulations, which play a crucial role in tumor immunity, may be critical for treatment 98 outcomes. We hypothesize that senolytics can be combined with ICIs to enhance their efficacy in 99 treating solid tumors.

100 In this study, we first explored the variability in patient responses to neoadjuvant 101 immunotherapy, starting with a Phase II clinical trial in head and neck squamous cell carcinoma 102 (HNSCC, NCT04718415). Further analysis of single-cell RNA sequencing (scRNA-Seq) data 103 from these patients allowed us to identify key immune cell subpopulations that influence 104 immune responses and to reveal the negative impact of immunosenescence on immunotherapy 105 efficacy. Additionally, animal study data highlighted the potential benefits of combining 106 senolytics with ICIs for treating solid tumors, including HNSCC, bladder cancer, and breast 107 cancer. We then initiated a pioneering Phase II clinical trial (COIS-01, NCT05724329) to 108 evaluate the efficacy and safety of combining anti-aging drugs with ICIs in HNSCC patients. 109 Our results indicate that the neoadjuvant combination of senolytics and ICIs significantly reduces 110 toxic side effects compared to neoadjuvant chemotherapy. Furthermore, patients receiving the 111 combination therapy exhibited a higher proportion of $CCR7⁺$ naïve T cells within their tumors,

112 suggesting a mitigation of immunosenescence and an enhancement of the adaptive immune 113 response.

114 **Phase II trial evaluating neoadjuvant chemotherapy combined with immunotherapy for** 115 **oral cavity and oropharyngeal squamous cell carcinoma (OOC-001)**

116 We enrolled 51 patients with stage II-IVA HNSCC for neoadjuvant chemoimmunotherapy 117 (OOC-001, NCT04718415). One patient was excluded from the evaluation due to refusing to 118 continue the treatment (Extended Data Fig. 1a). All patients underwent a minimum of two cycles 119 of neoadjuvant treatment, with 24 (47.1%) receiving 2 cycles, 23 (45.1%) receiving 3 cycles, and 120 4 (7.8%) receiving 4 cycles of neoadjuvant treatment (Supplementary Tables 1-4). Among the 48 121 evaluable patients, 23 patients achieved pathological complete response (pCR, 47.9%), 8 patients 122 achieved major pathological response (MPR, 16.7%), 10 patients showed partial pathological 123 response (pPR, 20.8%), and 7 patients displayed pathological no response (pNR, 14.6%) (Fig. 1a, 124 Extended Data Fig. 1b). The comparison of radiologic and pathologic response indicators 125 suggested that certain patients were pathologically assessed as pCR while radiologically assessed 126 as PR (Partial response)/SD (Stable disease), highlighting significant inconsistency between 127 pathological and radiological assessments (Fig. 1b). Compared to the baseline, 72.7% of primary 128 tumors exhibited shrinkage, while only 46.7% of patients showed regression in lymph nodes, 129 possibly indicating that primary tumors in HNSCC are more sensitive to neoadjuvant therapy 130 (Fig. 1c and Extended Data Fig. 1c-e). Regarding treatment cycles, pathological assessment 131 suggested that the efficacy of the 2-cycle treatment might be less than that of 3 or 4 cycles 132 (Extended Data Fig. 1f). 48 patients (94%) experienced at least one treatment-related adverse 133 effect (TRAE). Grade 3-4 TRAEs were observed in 26 patients (51%), and the most common 134 TRAEs were alopecia (75%), asthenia or fatigue (53%), and nausea (49%) (Supplementary Table

135 2).

136 The 24-month overall survival (OS) for the cohort was 93.9% (Extended Data Fig. 1g, h). 137 Our findings show that combining sintilimab with carboplatin and nab-paclitaxel resulted in 138 manageable side effects and achieved a high overall response rate (64.6%, MPR and pCR). 139 Considering the trade-off between anti-tumor effectiveness and adverse effects, we observed that 140 a 3-cycle treatment regimen offered superior benefits for patients with HNSCC.

141 **Immune landscape of HNSCC patients with neoadjuvant chemoimmunotherapy**

142 ScRNA-Seq and scT/BCR-Seq was performed in seven treatment-naïve tumor samples and 143 nine blood samples (including pre-and post-treatment) (Fig. 1d, Supplementary Table 3). 144 Following quality filtering, we obtained scRNA-Seq profiles as well as TCR and BCR 145 clonotypes from 143,056 cells, encompassing T cells, NK cells, B cells, myeloid cells, 146 fibroblasts, endothelium, and tumor cells (Supplementary Figure 1a-f). A total of 27 cell clusters 147 with distinct molecular features were observed by re-clustering each major immune cell type 148 (Fig. 1e).

149 We analyzed the abundance of various immune subtypes and compared their proportions 150 across the tumor, pre-treatment blood (P0) and post-treatment blood (P1) of MPR and noMPR patients. The proportion of $CD4^+$ T cells showed the largest elevation among all immune cell 152 types when comparing P1 to P0 (Supplementary Figure 1g, h). While compared to noMPR patients, MPR patients' tumors exhibited higher proportions of $CCR7⁺CD4$ Naïve T cells, 154 CXCL13⁺CD4 T cells, GZMK⁺CD8 Tem cells, and CD27⁺ Memory B cells. Conversely, the 155 proportions of FOXP3⁺CD4 Treg cells and IGF1⁺ macrophages (IGF1⁺ M φ) were lower (Fig. 1f 156 and Supplementary Figure 2, 3a-f). The upregulated genes in noMPR patients of the main T/B 157 cell subtypes were involved in aging-related pathways, indicating these pathways may contribute 158 to variations in the treatment response status of HNSCC patients. (Supplementary Figure 3g,

159 Supplementary Table 5). Using T/BCR diversity as markers of antigenic immune responses to 160 neoadjuvant therapy, we investigated TCR and BCR clonality in MPR and noMPR groups 161 through three different methods (Chao1, Shannon Index, and Richness). The results showed that 162 MPR patients exhibited higher TCR and BCR clonal diversity in $CCR7⁺CD4$ Naïve T cells, 163 CXCL13⁺CD4 T cells, GZMK⁺CD8 Tem cells, and CD27⁺ Memory B cells (Fig. 1g and 164 Supplementary Figure 3h). Additionally, dominant clones present in the tumor and blood before 165 treatment persisted as the dominant clones after treatment in MPR patients (Extended Data Fig. 166 2a-c). Further analysis of TCR/BCR clonotypes from P0, P1, and tumors revealed no significant 167 differences in TCR/BCR clonotypes in blood before and after treatment, nor between MPR and 168 noMPR patients. Interestingly, MPR patients exhibited a greater number of unique TCR/BCR 169 clonotypes within tumors, suggesting a richer TCR/BCR clonal diversity (Extended Data Fig. 2d, 170 e).

171 Immunosenescence refers to the decline in the immune system's ability to effectively respond to pathogens and cancer cells 11 . Recent studies have found that characteristics of 173 immunosenescence include an imbalance in the proportion of naïve and memory T cells, a decrease in the number of TCR clones, and elevated levels of $p16^{INK4a}$ (also known as *CDKN2A*) and $p21^{CIP1}$ (*CDKN1A*) expression ^{19,20}. We then examined the expressions of the senescent 176 markers, P16 and P21, by immunostaining in tumor tissues from two clinical trials conducted at 177 our center (OOC-001 and REDUCTION-I, NCT05582265). The results revealed that the tumor 178 microenvironment of noMPR patients exhibited higher levels of senescent features (Fig. 1h and 179 Extended Data Fig. 2f). In summary, our data suggests that non-responsive patients to 180 neoadjuvant treatment demonstrate dysregulation in immune cell proportions and an increase in 181 senescent characteristics.

182 **T cell and B cell subtypes exhibiting senescent features influence the response to** 183 **immunotherapy**

184 Recent studies have shown that in late life, the aging individual's adaptive immune system 185 exhibits dysfunction and increased autoimmunity, with T and B cell aging being a primary 186 manifestation of immunosenescence $2^{1,22}$. However, there is no gold standard marker for defining the senescence of T and B cells 23 . To figure out this assumption, we first created an 188 immunosenescence-associated gene set (IAGs) consists of 154 genes based on extensive scRNA-189 Seq datasets differentiating immune cells from young and elderly individuals (Extended Data Fig. 190 3a, Supplementary Table 6). The IAGs were significantly enriched in the immune cells of elderly 191 individuals in three independent scRNA-Seq datasets (GSE157007 24 , GSE141595 25 and 192 PRJCA002856) (Fig. 2a and Extended Data Fig. 3b-d), indicating they could reflect human 193 immunosenescence characteristics. Additionally, evaluating IAGs in scRNA-Seq datasets for $HNSCC$ and triple-negative breast cancer (TNBC) 26 immunotherapies also revealed lower 195 senescent scores in MPR patients compared to noMPR patients (Extended Data Fig. 3e). 196 Subsequently, we used IAGs to score T cells and their subtypes, which revealed lower 197 immunosenescence features in MPR patients with HNSCC (Fig. 2b and Extended Data Fig. 4a). 198 Furthermore, we also identified senescent genes associated with T cells from the IAGs, which 199 showed higher expression levels in multiple T cell subgroups of noMPR patients, with GO 200 analysis revealed enrichment in pathways related to S100 protein binding (Fig. 2c and Extended 201 Data Fig. 4b, c). Similar results were obtained from the TNBC dataset (Extended Data Fig. 4d-h).

202 Relative to noMPR patients, MPR patients exhibited lower $V\alpha/\beta$ gene usage frequencies in 203 CCR7⁺CD4 T cells and FOXP3⁺CD4 Treg cells in both tumors and blood, consistent with 204 previous findings (Extended Data Fig. 5a). Pseudotime analysis of immune cells revealed that 205 CD4⁺ T cell subsets in peripheral blood exhibit an early differentiation phenotype, while their

206 tumor counterparts show a more differentiated phenotype. Notably, MPR patients demonstrated 207 differentiation towards CCR7⁺CD4 Naïve T cells and CXCL13⁺CD4 Th cells, maintaining T cell 208 vitality and the potential to differentiate into various functional subtypes. In contrast, $CD4^+$ T 209 cells in non-MPR patients tended to differentiate towards $FOXP3⁺CD4$ Tregs, leading to 210 immunosenescence-related characteristics (Extended Data Fig. 5b-d).

211 Numerous T cells demonstrate shared clonotypes between tumors and blood. These clonal T 212 cells in tumor showed elevated IAGs scores than those in blood, suggesting a higher level of 213 senescent characteristics for the tumor-infiltrating T cells (Fig. 2d, e). Analysis of paired TCR 214 data revealed a notable reduction of both unique and total clonotypes particularly in the $CCRT⁺CD4$ Naïve T cells in noMPR patients compared with MPR patients (Fig. 2f). 216 Immunosenescence features are notably pronounced in B cells of noMPR patients, particularly in 217 CD27⁺ Memory B cells (Extended Data Fig. 6a-e). Pairwise analysis of T and B cell receptors 218 and ligands revealed strong interactions between FOXP3⁺CD4 Treg cells and CXCL13⁺CD4 T 219 helper cells with B cells (Extended Data Fig. 6f). This indicates that in MPR patients, the 220 reduced number of FOXP3⁺CD4 Tregs and increased number of CXCL13⁺CD4 T helpers may 221 exert their effects through interactions with B cells.

222 Through immunofluorescence staining, we confirmed that $CD4^+$ T cells and $CD27^+$ 223 memory B cells expressing the senescent marker S100A11 were more abundant in noMPR 224 patients, while no difference was observed in the number of $\text{S100A11}^+ \text{C} \text{D}8 \text{ T}$ cells between 225 noMPR and MPR patients, suggesting senescent status of CD4 T cells critically modulate 226 patients' response to neoadjuvant therapy (Fig. 2g and Extended Data Fig. 6g). Analysis of 227 HNSCC Patients' data from the TCGA database found that patients with high expression of IAGs 228 such as *S100A11*, *AREG*, *CALD1*, *CDKN1A*, and *CASP4* together with low CD4 Naïve T cell or 229 memory B cell abundance had significantly worse prognosis than those with low expression of

230 senescent genes and high proportions of CD4 Naïve T cells or memory B cells (Fig. 2h and 231 Supplementary Figure 4). T cells predict responses to immunotherapy more effectively in 232 HNSCC patients, while in TNBC patients, B cells are more predictive (Fig. 2i). These analyses 233 suggest that the IAGs we constructed were effective in distinguishing the immune cells of 234 noMPR and MPR patients, and that lower expression levels of IAGs in $CCR7⁺CD4$ Naïve T and 235 CD27⁺ Memory B cells are associated with a positive treatment response.

IGF1⁺ **M_ø induce senescent characteristics in T cells**

237 Innate immune cells play an important role in early tumor cell recognition and subsequent 238 initiation of inflammation and antitumor responses. To investigate whether non-lymphocyte 239 immune cells are involved in the immunosenescence phenotype observed in our study subjects, 240 we analyzed the gene expression features of myeloid cells. $IGF1^+$ M ϕ exhibited the highest 241 differentiation score among all myeloid cell types according to pseudotime analysis (Extended 242 Data Fig. 7a). The precursor cells of $IGF1^+$ M φ in the blood are IL1B-CD14 cells, which showed 243 significant changes in the MPR group before and after treatment. Interestingly, the proportion of IGF1⁺ 244 Mφ within tumors and IL1B-CD14 cells in blood were significantly higher in noMPR 245 patients (Fig. 2j and Extended Data Fig. 7b-d). Additionally, $IGF1^+$ M ϕ negatively correlated 246 with CCR7+CD4 Naïve T cells and CD27+ Memory B cells in tumors (Fig. 2k). We also 247 examined the composition proportions of myeloid cell subtypes in TNBC patients and found that 248 PR patients had a higher proportion of $IGF1^+$ M φ compared to SD patients, consistent with our 249 HNSCC results (Extended Data Fig. 7e, f). By scoring the expression of six major senescence-250 associated secretory phenotype (SASP) factors in HNSCC and TNBC, we found that IL1B-CD14 monocytes and $IGF1^+$ M φ expressed higher levels of SASP factors compared to other 252 myeloid cell subtypes (Extended Data Fig. 7g, h). Interaction analysis further revealed that 1253 IGF1⁺ M_φ had a strong potential for interaction with T cells (Supplementary Figure 5a-c).

 254 Enrichment analysis of pathways related to $IGF1⁺$ M ϕ and IL1B-CD14 cells revealed 255 involvement in senescent and inflammatory pathways, including ERK, MAPK and IL-1 256 pathways. Consequently, $IGF1^+$ M φ in the TIME may induce immunosenescence in T cells. 257 Analysis of TCGA data for HNSCC patients demonstrated that those with high IGF1 signature 258 had relatively poor OS and progression-free survival (PFS) (Extended Data Fig. 7i and 259 Supplementary Figure 5d, e). In conclusion, our analysis of myeloid cell subtypes suggests that 260 IGF1⁺ M₀ could be a crucial factor contributing to the limited response of tumor patients to 261 immunotherapy. These cells may trigger an immunosenescent status in the TIME through their 262 interactions with T cells.

²⁶³**Senolytics combined** α**PD-1 alleviate TIME senescent burden in HNSCC**

264 Currently, the role of the senescent phenotype in HNSCC and its interaction with tumor 265 cells, immune cells, or other cell types remains poorly understood. The impact of senolytics 266 treatments or their combination with other therapies in HNSCC is yet to be determined. 267 Histochemical staining with β-galactosidase revealed a significantly more pronounced senescent 268 phenotype in HNSCC tissue compared to the adjacent normal tissue (Fig. 3a). Then, we 269 established a 4-NQO-induced (4-Nitroquinoline-N-oxide) HNSCC mouse model using 12- 270 month-old C57BL/6 (C57) mice (Fig. 3b). The mice underwent the typical progression of normal 271 epithelium-epithelial dysplasia-invasive cancer, with an average age of tumor occurrence around 272 20 months, reflecting the real progression of HNSCC in elderly patients more accurately 273 (Extended Data Fig. 8a). Immunofluorescence staining on tumor sections confirmed significantly 274 higher expression of the key senescent marker P16 in the tumor region compared to surrounding 275 normal tissue (Fig. 3c).

287 Subsequently, we evaluated changes in $CD4^+$, $CD8^+$, and $B220^+$ cells in the spleen, blood, 288 bone marrow, and tumors across different treatment groups using flow cytometry. The αPD-289 1+DQ group showed an increased proportion of $CD4^+$ cells within tumors, while $CD8^+$ and $B220⁺$ cell levels exhibited no significant differences compared to other groups (Fig. 3h). Similar results were observed in the spleen (Extended Data Fig. 8d, e). However, $B220^+$ cell counts were 292 relatively elevated in peripheral blood samples from the α PD-1+DQ group (Extended Data Fig. 293 8f-g). Additionally, the expression levels of *p16* and *p21* were significantly reduced in tumor-294 infiltrating $CD4^+$ cells from the α PD-1+DQ group (Fig. 3i), whereas no significant differences were noted in $CD8⁺$ cells (Extended Data Fig. 8h). Furthermore, an increased proportion of 296 CD62L⁺CD44⁻ naïve CD4⁺ cells was observed in the αPD-1+DQ group (Fig. 3j). 297 Immunofluorescence staining consistently confirmed a significant increase in $CD4^+CD62L^+$ cells 298 in the α PD-1+DQ group relative to the other groups (Fig. 3k and Supplementary Figure 6). 299 Together, these findings suggest that immunosenescence in HNSCC surpasses that in

300 surrounding normal tissue, and the combination of αPD-1+DQ may enhance the therapeutic 301 efficacy of α PD-1 by mitigating the senescent phenotype of tumor immune cells, particularly in 302 CD4⁺ cells.

Synergistic reduction of SASP and increase in CD4⁺ ³⁰³**Naïve T cells by senolytics and** α**PD-1** 304 **in solid tumors**

305 To determine the effectiveness of α PD-1+DO in various transplant tumor models, including 306 HNSCC, we established two mouse oral squamous cell carcinoma cell lines, 4N-MS1 and 4N-307 MS2, from the 4-NQO model (Fig. 4a, Extended Data Fig. 9a, b). To simulate the systemic so senescence in normal elderly mice, we used $\text{Erccl}^{+\prime-}$ mice, which exhibit rapid senescent 309 characteristics such as hair loss and graying like 20-month-old wild-type mice by the age of 10 310 months (Fig. 4b). Further measurements of spleen weight and 8-hydroxy-2-deoxyguanosine (8- 311 OHdG) content in the spleen showed that *Ercc1^{+/-}* 10m mice had similar 8-OHdG levels and 312 spleen weight as WT 20m mice. Immunofluorescence staining revealed that 10-month-old *Ercc1^{+/-}* mice expressed more γH2AX in the spleen, heart, liver, and lungs compared to wildtype mice (Fig. 4c-e). In summary, *Ercc1^{+/-}* 10m mice exhibited senescent characteristics like 315 naturally aging wild-type mice.

We implanted 4N-MS1cells into the tongues of 10-month-old $\text{E}rcc1^{+/}$ mice and, on the 5th 317 day, treated the mice with Isotype, α PD-1, α PD-1+CP, or α PD-1+DQ (Fig. 4f). Tumor growth 318 curves showed that mice in the α PD-1+DQ group had better treatment outcomes than other 319 groups (Fig. 4g). Additionally, we employed the Multiplex bead-based protein analysis method 320 to measure the expression of various SASP factors in tumor tissue lysates. The results revealed 321 that αPD-1+DQ treatment significantly reduced the expression of various SASP factors within 322 the tumor, including IL-2, TNF-α, IFN-γ, IL-10, CCL20, MCP-3, and others (Fig. 4h and

323 Supplementary Table 7). Furthermore, flow cytometric analysis showed an increase in CD62L⁺CD44⁻CD4⁺ Naïve cells in the α PD-1+DQ group compared to the Isotype group (Fig. 4i). Consistently, immunofluorescence staining confirmed a significant decrease of $P21⁺$ cells in the 326α aPD-1+DO group compared to the other three groups (Fig. 4j). Moreover, we implanted MB49 (bladder cancer) and E0771 (breast cancer) tumors subcutaneously in 10-month-old *Ercc1+/-* ³²⁷ 328 mice and observed therapeutic outcomes like those seen with the 4N-MS1 transplant model. (Fig. 329 4k and Extended Data Fig. 9c-f). In summary, these data suggest that α PD-1+DQ treatment can 330 suppress tumor growth in multiple solid tumors while enhancing immune microenvironment 331 vitality through reduced SASP and increased $CD4^+$ Naïve cells.

332 **Senolytics reduce senescent characteristics and enhance activation of tumor-infiltrating CD4⁺** ³³³**Naïve T cells**

 334 To investigate the unique functionality of significantly increased $CD4^+CD62L^+$ Naïve T 335 cells in tumors after combined α PD-1+DQ therapy in anti-tumor immunity, we isolated CD62L⁺CD44⁻CD4⁺ cells from tumors of mice treated with Isotype, αPD-1, or αPD-1+DQ, and 337 performed RNA-Seq and ATAC-Seq (Fig. 5a). The results of RNA-Seq showed that, compared 338 to Isotype or α PD-1 treatment, the α PD-1+DQ group exhibited significantly higher expression of 339 genes related to T-cell migration (*Ccr7*) or antigen response (*Lck*, *Cfd*) in Naïve T cells (Fig. 5b, 340 Extended Data Fig. 10a and Supplementary Table 8). GO analysis revealed enrichment in 341 pathways related to T-cell maintenance, differentiation, and antigen presentation for both αPD-342 1+DQ and Isotype groups, indicating that the combination of senolytics with αPD-1 may 343 enhance immune response levels by promoting proliferation and differentiation of Naïve T cells 344 (Fig. 5c and Extended Data Fig. 10b). Additionally, ATAC-Seq analysis demonstrated that, 345 relative to Isotype or α PD-1 treatment, the α PD-1+DQ group exhibited significantly higher 346 chromatin accessibility of the *Ccr7* gene, crucial for adaptive immune responses. Conversely,

359 **Combination of anti-PD-1 with Dasatinib and Quercetin Demonstrates Safety and Efficacy** 360 **in Patients with HNSCC**.

361 Previous studies have indicated that neoadjuvant chemotherapy reduces recurrence in 362 patients with locally advanced oral cancer but does not improve survival rates 27.28 . Recent 363 research indicates that chemotherapy can exacerbate the adverse effects associated with 364 immunotherapy. The most prevalent adverse effects of neoadjuvant immunochemotherapy 365 include alopecia (100.0%), nausea/vomiting (60.4%), and fatigue (50.0%) 29 . Therefore, it is 366 essential to investigate novel therapeutic agents that can enhance the efficacy of immunotherapy 367 while minimizing systemic side effects, preserving the function of vital organs, and ultimately 368 improving the quality of life for patients.

369 Based on our findings from single-cell multi-omics analysis and animal models, we 370 hypothesized that combining ICIs with dasatinib and quercetin would be both effective and safe 371 for patients with HNSCC, significantly reducing TRAEs compared to standard neoadjuvant 372 chemotherapy. To evaluate this hypothesis, we conducted a prospective, open-label, single-373 center, Phase II clinical trial (COIS-01), assessing the neoadjuvant efficacy of tislelizumab 374 combined with dasatinib and quercetin in resectable HNSCC patients. The primary endpoint of 375 the study was the MPR rate (Fig. 6a). Between February 5, 2023, and April 5, 2024, a total of 24 376 patients were enrolled according to the study protocol. Efficacy evaluations revealed that 4 377 patients (16.7%) achieved a pCR, while another 4 (16.7%) achieved a MPR, resulting in an 378 overall treatment response rate of 33.3% (pCR + MPR) (Fig. 6b and Supplementary Table 10). 379 Representative imaging, pathological assessments, and clinical photographs of patients achieving 380 pCR are provided (Fig. 6c).

381 Safety analyses of the 24 patients demonstrated that only 1 patient experienced grade 3-4 382 TRAEs (Fig. 6d). In contrast, the OOC-001 trial, which evaluated neoadjuvant chemotherapy, 383 showed the most common TRAEs were alopecia (75%), asthenia or fatigue (53%), and nausea 384 (49%) (Fig. 6e, Supplementary Table 2). In the COIS-01 trial, the corresponding incidences were 385 notably lower, with 0% for alopecia, 25% for asthenia or fatigue, and 16.7% for nausea 386 (Supplementary Table 11). Although the survival period in COIS-01 has not yet allowed for 387 statistical analysis of overall survival, no recurrences or deaths have been observed to date. 388 Furthermore, immunohistochemical analysis of patient paraffin sections before and after αPD-1 389 + DQ treatment revealed an upregulation of CCR7 expression in naïve T cells post-treatment 390 (Fig. 6f). These early findings from the COIS-01 trial suggest that the combination of 391 tislelizumab with dasatinib and quercetin demonstrates promising antitumor efficacy, favorable 392 tolerability, and a potential to mitigate immunosenescence-related features.

393

394 **Discussion**

395 The central conclusion of this study is that the senescence of TIME is a critical factor 396 affecting the efficacy of tumor immunotherapy. The first evidence supporting this conclusion 397 comes from the multidimensional single-cell data analysis of immune cells from both blood and 398 tumors of patients in clinical trials. We observed that noMPR patients exhibited more 399 pronounced immunosenescence features, including a decreased proportion of naïve T cells and 400 memory B cells, an increased proportion of immunosuppressive cell subtypes, and a reduction in 401 the TCR/BCR repertoire. Additionally, we identified IAGs in immune cells from noMPR 402 patients, which showed higher expression levels across various T and B cell subsets. When 403 tumor-bearing mice received a combination of ICI and senolytics, we observed an increase in CD4⁺ 404 naïve T cells and a reduction in senescence markers in immune cells within the tumors. 405 This led to reduced tumor burden and extended survival in the mice. A clinical trial based on our 406 findings further confirmed the potential advantage of combining ICI with senolytics for treating 407 solid tumors.

Immune cells are the cornerstone of tumor immunotherapy $30,31$. T cell-centered therapies 409 have become powerful tools against cancer. ICI is the most widely used immunotherapy method 410 for solid malignancies, with an increasing number of monoclonal antibodies targeting different 411 inhibitory receptors entering clinical practice 32 . Antibodies against PD-1, CTLA-4, and LAG-3 412 have been FDA-approved for several types of solid tumors. Although ICI can induce objective 413 responses even in the challenging context of metastatic disease, only a minority of patients 414 (estimated at $\langle 30\% \rangle$ achieve sustained and/or complete clinical responses $^{33-35}$. The TIME is rich 415 in tumor-reactive T cells, but exhaustion remains a major factor limiting their antitumor

416 capabilities. Studies on chronic antigen stimulation models in mice $36-38$ and the characteristics of tumor-infiltrating lymphocytes (TILs) in human "hot" tumors $39-41$ emphasize that antitumor T 418 cells can progressively acquire a dysfunctional state, allowing tumor immune evasion $42,43$. These 419 findings suggest that the TIME is not isolated but interconnected with the systemic immune 420 system. The dynamic processes of TILs dysfunction and continuous recruitment of immune cells 421 to the tumor provide a new perspective for exploring ways to improve the TIME during tumor 422 progression.

423 Notably, our study shows no significant differences in the proportions of most immune cell 424 types in the peripheral blood of responsive and non-responsive patients before and after 425 treatment. This indicates that predicting immunotherapy responses based on peripheral blood 426 tests may be challenging. Although cellular senescence drives various age-related complications through SASP, identifying senescent immune cells in vivo remains difficult ^{44–46}. Recent studies 428 have identified a set of genes (SenMayo) enriched in bone biopsies from elderly individuals, 429 capable of identifying senescent hematopoietic or stromal cells at the single-cell level in human 430 and mouse bone marrow/bone scRNA-Seq data 46 . Researchers also established AgeAnno, a 431 human aging single-cell annotation knowledge base, offering dynamic functional annotations of $1,678,610$ cells from 28 healthy tissue samples 47 . Currently, there are no specific markers or 433 gene sets dedicated to reflecting the degree of immunosenescence. We have constructed an 434 immunosenescence-related gene set comprising 154 genes (IAGs), which has effectively 435 distinguished between young and elderly individuals in external datasets. This provides a 436 powerful tool for future research on the senescent status of the immune system. It is important to 437 note that the immune system consists of diverse cell types, each with distinct functions. For 438 example, the gene expression profiles of senescent states in T cells, dendritic cells, and

19

439 macrophages may differ significantly. Understanding these differences is crucial for developing 440 targeted therapies for senescent phenotypes.

441 Senolytics therapies for various cancers are currently under investigation. Studies have 442 shown that senolytics ABT-263 can exert antitumor effects by selectively clearing senescent quared 443 cells in obese patients' tumor tissues 48 . Additionally, the plant compound Rutin, when combined 444 with chemotherapy, can intervene in tumor development 49 . These studies suggest that senolytics 445 may offer unique advantages in cancer treatment, with fewer side effects and promoting overall 446 systemic health. However, the combination of senolytics and ICI has not been explored in TIME. 447 Previous research discussed the potential benefits of DQ therapy, a novel senolytics regimen that 448 disrupts survival pathways of senescent cells and selectively targets them $50-52$. Recent research 449 on systemic administration of DQ for treating intervertebral disc degeneration has provided new 450 insights, highlighting the tissue-specific effects of DQ and the importance of treatment timing 53 . 451 Additionally, a clinical trial on DQ treatment for idiopathic pulmonary fibrosis (IPF) 452 demonstrated significant improvements in patients' physical function $54,55$. Our COIS-01 trial has 453 demonstrated the efficacy and safety of combining senolytics with ICIs in HNSCC patients. 454 Previous studies have shown that ICIs monotherapy in HNSCC has limited effectiveness, with 455 reported MPR rates of $7-13.9\%$ ^{56–58}. In contrast, the COIS-01 trial achieved an MPR rate of 456 33.3%. While immunochemotherapy can achieve higher MPR rates, it is associated with 457 significant toxicity, with grade ≥ 3 adverse events occurring in up to 35% of patients ⁵⁹, 458 substantially higher than in the COIS-01 trial, where the incidence of such events was 459 considerably lower (4.2%). Grade ≥3 toxicities can severely impact patient quality of life and 460 pose challenges for subsequent adjuvant immunotherapy. Discontinuation of adjuvant

461 immunotherapy due to toxicity may compromise the overall therapeutic efficacy, potentially 462 affecting survival outcomes 60 .

463 Given this balance between efficacy and risk, the COIS-01 trial offers a novel therapeutic 464 strategy that maximizes the antitumor efficacy of ICIs while minimizing adverse events. 465 Preclinical studies in multiple mouse models have demonstrated the superior potential for long-466 term survival with the combination of α PD-1 and senolytics (dasatinib and quercetin) compared 467 to monoimmunotherapy or immunochemotherapy. Consistently, the combination of senolytics 468 and anti-PD-1 therapy has been shown to dramatically upregulate $CCR7⁺$ naïve T cells in COIS- 01 patients, a critical feature in the modulation of immunosenescence 61 . This upregulation 470 enhances the homing 62 , immune surveillance 63 , and circulating maintenance 64 of these specific 471 T cells, potentially predicting improved survival outcomes in clinical settings. However, rigorous 472 randomized clinical trials are needed to further validate these findings. Additionally, further 473 investigation is required to determine the optimal type and dosage of senolytics in combination 474 with ICIs.

475 In summary, this study provides valuable insights into the variability of the tumor immune 476 microenvironment (TIME) across individuals and highlights the potential for enhancing 477 antitumor efficacy by targeting immunosenescence within the TIME. These findings offer a 478 promising avenue for improving outcomes in patients with HNSCC.

479

480 **References**

- 481 1. Cramer, J. D., Burtness, B. & Ferris, R. L. Immunotherapy for head and neck cancer: Recent advances and 482 future directions. *Oral Oncology* **99**, 104460 (2019).
- 483 2. Bernier, J. *et al.* Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced 484 Head and Neck Cancer. *The New England Journal of Medicine* (2004).

- 485 3. Cooper, J. S. *et al.* Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell 486 Carcinoma of the Head and Neck. *N Engl J Med* **350**, 1937–1944 (2004).
- 487 4. Puram, S. V. *et al.* Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head 488 and Neck Cancer. *Cell* **171**, 1611-1624.e24 (2017).
- 489 5. Li, J. *et al.* Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-490 deficient colorectal cancer. *Cancer Cell* **41**, 1152-1169.e7 (2023).
- 491 6. Oliveira, G. & Wu, C. J. Dynamics and specificities of T cells in cancer immunotherapy. *Nat Rev Cancer* **23**,

492 295–316 (2023).

- 493 7. Bhatia, A. & Kumar, Y. Cellular and molecular mechanisms in cancer immune escape: a comprehensive 494 review. *Expert Review of Clinical Immunology* **10**, 41–62 (2014).
- 495 8. Tumeh, P. C. *et al.* PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature* **515**, 496 568–571 (2014).
- 497 9. Galon, J. *et al.* Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. *The* 498 *Journal of Pathology* **232**, 199–209 (2014).
- 499 10. Fridman, W. H., Pagès, F., Sautès-Fridman, C. & Galon, J. The immune contexture in human tumours: impact 500 on clinical outcome. *Nat Rev Cancer* **12**, 298–306 (2012).
- 501 11. Yousefzadeh, M. J. *et al.* An aged immune system drives senescence and ageing of solid organs. *Nature* **594**, 502 100–105 (2021).
- 503 12. Goronzy, J. J. & Weyand, C. M. Understanding immunosenescence to improve responses to vaccines. *Nat* 504 *Immunol* **14**, 428–436 (2013).
- 505 13. Liu, Z. *et al.* Immunosenescence: molecular mechanisms and diseases. *Sig Transduct Target Ther* **8**, 200 506 (2023).
- 507 14. Zinatizadeh, M. R. *et al.* Immunosenescence and inflamm-ageing in COVID-19. *Ageing Research Reviews* **84**, 508 101818 (2023).
- 509 15. Ferrara, R. *et al.* Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer 510 Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. *Clinical Cancer Research* 511 **27**, 492–503 (2021).
- 512 16. Lian, J., Yue, Y., Yu, W. & Zhang, Y. Immunosenescence: a key player in cancer development. *J Hematol* 513 *Oncol* **13**, 151 (2020).

- 514 17. Liu, X. *et al.* Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor
- 515 immunity and immunotherapy. *J Immunother Cancer* **10**, e005020 (2022).
- 516 18. Park, M. D. *et al.* Hematopoietic aging promotes cancer by fueling IL-1^{D}-driven emergency myelopoiesis. 517 *Science* eadn0327 (2024) doi:10.1126/science.adn0327.
- 518 19. Vicente, R., Mausset-Bonnefont, A.-L., Jorgensen, C., Louis-Plence, P. & Brondello, J.-M. Cellular senescence 519 impact on immune cell fate and function. *Aging Cell* **15**, 400–406 (2016).
- 520 20. Pinti, M. *et al.* Aging of the immune system focus on inflammation and vaccination. (2017).
- 521 21. Mittelbrunn, M. & Kroemer, G. Hallmarks of T cell aging. *Nat Immunol* **22**, 687–698 (2021).
- 522 22. López-Otín, C. Hallmarks of aging: An expanding universe.
- 523 23. Swanton, C. *et al.* Embracing cancer complexity: Hallmarks of systemic disease. *Cell* **187**, 1589–1616 (2024).
- 524 24. Luo, O. J. *et al.* Multidimensional single-cell analysis of human peripheral blood reveals characteristic features 525 of the immune system landscape in aging and frailty. *Nat Aging* **2**, 348–364 (2022).
- 526 25. Weivoda, M. M. *et al.* Identification of osteoclast-osteoblast coupling factors in humans reveals links between 527 bone and energy metabolism. *Nat Commun* **11**, 87 (2020).
- 528 26. Zhang, Y. *et al.* Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 529 blockade in triple-negative breast cancer. *Cancer Cell* **39**, 1578-1593.e8 (2021).
- 530 27. Marta, G. N. *et al.* Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral 531 cavity cancer patients: Systematic review and meta-analysis. *Eur J Cancer* **51**, 2596–2603 (2015).
- 532 28. Liu, J. *et al.* Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic 533 Disease. *Cancer Discov* **6**, 1382–1399 (2016).
- 534 29. D, W. *et al.* Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in 535 resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial. *Nature* 536 *communications* **15**, (2024).
- 537 30. Sharma, P. & Allison, J. P. Dissecting the mechanisms of immune checkpoint therapy. *Nat Rev Immunol* **20**, 538 75–76 (2020).
- 539 31. Restifo, N. P., Dudley, M. E. & Rosenberg, S. A. Adoptive immunotherapy for cancer: harnessing the T cell 540 response. *Nat Rev Immunol* **12**, 269–281 (2012).
- 541 32. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. *Science* **348**, 56–61 (2015).

- 544 34. Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to 545 immune checkpoint blockade. *Cell* **184**, 5309–5337 (2021).
- 546 35. De Miguel, M. & Calvo, E. Clinical Challenges of Immune Checkpoint Inhibitors. *Cancer Cell* **38**, 326–333 547 (2020).
- 548 36. Im, S. J. *et al.* Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. *Nature* **537**, 417– 549 421 (2016).
- 550 37. Siddiqui, I. *et al.* Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in 551 Response to Vaccination and Checkpoint Blockade Immunotherapy. *Immunity* **50**, 195-211.e10 (2019).
- 552 38. Utzschneider, D. T. *et al.* T Cell Factor 1-Expressing Memory-like CD8+ T Cells Sustain the Immune 553 Response to Chronic Viral Infections. *Immunity* **45**, 415–427 (2016).
- 554 39. Sade-Feldman, M. *et al.* Defining T Cell States Associated with Response to Checkpoint Immunotherapy in 555 Melanoma. *Cell* **175**, 998-1013.e20 (2018).
- 556 40. Li, H. *et al.* Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within 557 Human Melanoma. *Cell* **176**, 775-789.e18 (2019).
- 558 41. Van Der Leun, A. M., Thommen, D. S. & Schumacher, T. N. CD8+ T cell states in human cancer: insights 559 from single-cell analysis. *Nat Rev Cancer* **20**, 218–232 (2020).
- 560 42. Thommen, D. S. & Schumacher, T. N. T Cell Dysfunction in Cancer. *Cancer Cell* **33**, 547–562 (2018).
- 561 43. Philip, M. & Schietinger, A. CD8+ T cell differentiation and dysfunction in cancer. *Nat Rev Immunol* **22**, 209– 562 223 (2022).
- 563 44. Baker, D. J. *et al.* Naturally occurring p16Ink4a-positive cells shorten healthy lifespan. *Nature* **530**, 184–189 564 (2016).
- 565 45. Xu, M. *et al.* Senolytics improve physical function and increase lifespan in old age. *Nat Med* **24**, 1246–1256 566 (2018).
- 567 46. Saul, D. *et al.* A new gene set identifies senescent cells and predicts senescence-associated pathways across 568 tissues. *Nat Commun* **13**, 4827 (2022).
- 569 47. Huang, K. *et al.* AgeAnno: a knowledgebase of single-cell annotation of aging in human. *Nucleic Acids* 570 *Research* **51**, D805–D815 (2023).

- 571 48. Chang, J. *et al.* Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. *Nat* 572 *Med* **22**, 78–83 (2016).
- 573 49. Liu, H. *et al.* Rutin is a potent senomorphic agent to target senescent cells and can improve chemotherapeutic 574 efficacy. *Aging Cell* **23**, e13921 (2024).
- 575 50. Schafer, M. J. *et al.* Cellular senescence mediates fibrotic pulmonary disease. *Nat Commun* **8**, 14532 (2017).
- 576 51. Farr, J. N. *et al.* Targeting cellular senescence prevents age-related bone loss in mice. *Nat Med* **23**, 1072–1079 577 (2017).
- 578 52. Zhang, P. *et al.* Senolytic therapy alleviates Aβ-associated oligodendrocyte progenitor cell senescence and 579 cognitive deficits in an Alzheimer's disease model. *Nat Neurosci* **22**, 719–728 (2019).
- 580 53. Novais, E. J. *et al.* Long-term treatment with senolytic drugs Dasatinib and Quercetin ameliorates age-581 dependent intervertebral disc degeneration in mice. *Nat Commun* **12**, 5213 (2021).
- 582 54. Hickson, L. J. *et al.* Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of 583 Dasatinib plus Quercetin in individuals with diabetic kidney disease. *EBioMedicine* **47**, 446–456 (2019).
- 584 55. Justice, J. N. *et al.* Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot 585 study. *EBioMedicine* **40**, 554–563 (2019).
- 586 56. Jd, S. *et al.* Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell 587 Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. *JAMA oncology* **6**, (2020).
- 588 57. R, U. *et al.* Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human 589 Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. *Clinical cancer research: an* 590 *official journal of the American Association for Cancer Research* **26**, (2020).
- 591 58. Wise-Draper, T. M. *et al.* Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable 592 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma. *Clin Cancer Res* **28**, 1345–1352
- 593 (2022).
- 594 59. Zinner, R. *et al.* 968P Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) outcomes in 595 HPV(-) resectable locally advanced head and neck cancer. *Annals of Oncology* **31**, S682 (2020).
- 596 60. Ce, H. *et al.* Adjuvant immunotherapy: the sting in the tail. *European journal of cancer (Oxford, England:* 597 *1990)* **132**, (2020).

- 608 **Methods:**
- 609

610 **Human specimens**

611 This study includes three independent clinical trials for HNSCC: OOC-001 (NCT04718415), 612 REDUCTION-I (NCT05582265), and COIS-01 (NCT05724329). Eligible HNSCC patients 613 received prior approval from the Institutional Review Board (IRB) at Sun Yat-sen Memorial 614 Hospital, Sun Yat-sen University, and were required to provide written informed consent to 615 participate in the study. All patients were diagnosed with HNSCC by expert histopathologists, 616 and all invasive procedures and systemic treatments were ordered by the patients' attending 617 physicians, individually determined based on the response after the administration of 618 pharmacological drugs. The eight patients used for the scRNA-Seq study were part of the OOC-619 001 clinical trial and received the described treatment regimen. Specifically, all patients had their 620 primary tumor tissue and peripheral blood collected through biopsy at the time of enrollment, 621 and the peripheral blood was collected after sintilimab in combination with carboplatin and nab-622 paclitaxel treatment before surgery. Among the 7 patients (SH1-SH7) who underwent surgery, 3

623 patients are MPR, and 4 patients are noMPR. Paired biopsy samples of primary tumor tissue and 624 peripheral blood were collected at baseline before treatment, and peripheral blood samples were 625 collected 3 weeks after the first dosing cycle. Except for SH1, peripheral blood samples were 626 collected from the other patients before and after the first medication cycle for matching. For 627 patient SH1, blood samples were collected only before the first medication cycle. Peripheral 628 blood samples were collected after the second medication cycle for SH1, SH2, SH3, and SH4, 629 and peripheral blood samples were collected for SH3, SH4, and SH7 after the third medication 630 cycle. Paraffin sections from two ongoing clinical study patient cohorts were used for 631 immunofluorescence staining of senescent markers P16 and P21. This included 33 MPR patients 632 and 17 noMPR patients from OOC-001, as well as 37 MPR patients and 24 noMPR patients 633 from REDUCTION-I. Another set from COIS-01 collected paraffin sections from 7 patients for 634 immunofluorescence staining before and after treatment.

635 **Sample collection and processing**

636 Peripheral blood mononuclear cells (PBMCs) were isolated according to the manufacturer's 637 protocol. Briefly, before the start of treatment, 5 mL of fresh peripheral blood was collected in 638 EDTA anticoagulated tubes and subsequently extracted with LymphoprepTM (Stem Cells) 639 solution. After centrifugation, carefully transfer lymphocytes to a new 50 mL tube and wash with 640 PBS. Next, incubate the lymphocytes for 10 minutes to lyse the blood cells. Finally, cells were 641 resuspended in sorting buffer containing PBS plus 2% FBS.

642 For tumor biopsy samples, cut tissue with a diameter of about 5 mm at the junction of the 643 tumor and normal tissue as a representative sample. All 7 tumor biopsy samples were collected 644 as a discovery cohort through routine clinical practice and then stored in MACS Tissue Storage 645 Solution (Miltenyi). Fresh biopsy samples of oral HNSCC were minced and isolated using a 646 human tumor isolation kit (Miltenyi), followed by enzymatic digestion on a rotor at 37°C for 45–

647 60 min. The detached cells were then passed through 70 μm and 40 μm cell filters (Biosharp) 648 and centrifuged at $300 \times g$ for 10 min. Pelleted cells were suspended in red blood cell lysis buffer 649 (Thermo-Fisher) and incubated on ice for 2 min, then washed and resuspended in phosphate 650 buffer supplemented with 2% fetal bovine serum (FBS, ExCell) PBS twice in saline (PBS, 651 Gibco). The viability of all samples was confirmed to be >90% using the trypan blue (Thermo-652 Fisher) exclusion method.

653 **Single-cell RNA-seq library and TCR-seq library preparation and sequencing**

654 According to the manufacturer's protocol, scRNA-seq libraries were constructed. In 655 summary, the density of cells was determined after washing once with PBS containing 0.04% 656 bovine serum albumin (BSA, Invitrogen). Next, 2×10^5 cells were loaded on a 10x Genomics 657 GemCode Single cell instrument (10x Genomics) that generates single-cell Gel Bead-In-658 EMulsion (GEMs). Libraries were generated and sequenced from the cDNAs with the 659 Chromium Next GEM Automated Single Cell 3' cDNA Kitv3.1 (10x Genomics). Upon 660 dissolution of the Gel Bead in a GEM, primers were released and mixed with cell lysate and 661 Master Mix. Barcoded, full length cDNAs were then reverse-transcribed from polyadenylated 662 mRNA. Full-length, barcoded cDNAs were then amplified by quantitative real-time PCR 663 (qRT \Box PCR) for library construction. Finally, single-cell RNA libraries were sequenced by an 664 Illumina HiSeq X Ten sequencer with 150 bp paired-end reads.

665 After reverse transcription and cell barcoding, the cDNA was de-emulsified and purified 666 using silane magnetic beads, followed by PCR amplification. The amplified cDNA was then 667 used for 5' gene expression library construction and TCR V(D)J targeted enrichment 668 amplification using the Illumina® bridge. Libraries prepared according to the manufacturer's 669 user guide were then purified and analyzed for quality assessment. Single-cell RNA and TCR

670 V(D)J libraries were sequenced by an Illumina HiSeq X Ten sequencer using 150 bp paired-end 671 reads.

-
-

672 **Bulk TCR-seq library preparation and sequencing**

673 Whole Blood Samples Blood was collected in EDTA tubes and sent to isolated PBMCs, and 674 DNA was extracted for TCRβ analysis by immunoSEQ $⁶⁵$. Briefly, extracted genomic DNA was</sup> 675 amplified using a bias-controlled multiplex PCR system, followed by high-throughput 676 sequencing. Raw data processing and analysis were performed by immunoSEQ. Subsequently, 677 we used the International ImMunoGeneTics Information System (IMGT; http://imgt.cines.fr) 678 database for comparison. After the alignment, the relative abundance of each TCRβ CDR3 679 sequence was clarified and calculated. Furthermore, we use batch correction to eliminate batch 680 effects across different datasets. Subsequently, multiple TCR data statistics were performed.

681 **Bulk ATAC and RNA isolation and sequencing**

682 Isolation, library construction and sequencing of bulk ATAC and RNA were performed at 683 Gene Denovo Biotechnology Co. (Guangzhou, China). For ATAC sequencing, CD4 naïve cells 684 from C57 mouse tongue tumors were extracted. Tn5 transposase was added to the nuclear 685 suspension. After the reaction was completed, the DNA fragment was purified; the amplified 686 product was then used for PCR amplification. The fragments were purified using AMPure XP 687 magnetic beads (Beckman Coulter, Brea, CA, USA) to construct a sequencing library. After the 688 library construction was completed, Agilent 2100 (Agilent, Santa Clara, CA) was used to detect 689 the quality of the library. Libraries that pass the quality inspection will be used for on-machine 690 sequencing (Novaseq 6000) to obtain sequence information of the open chromatin region 691 fragments to be tested.

692 Extraction of CD4 naïve cells from C57 mouse tongue tumors. Total RNA was extracted 693 using Trizol reagent kit (Invitrogen) according to the manufacturer's protocol. RNA quality was

694 assessed on an Agilent 2100 Bioanalyzer (Agilent Technologies). After total RNA was extracted, 695 eukaryotic mRNA was enriched by Oligo(dT) beads. Then the enriched mRNA was reversely 696 transcribed into cDNA by using NEBNext Ultra RNA Library Prep Kit for Illumina (NEB #7530, 697 New England Biolabs). The resulting cDNA library was sequenced using Illumina Novaseq6000 698 by Gene Denovo Biotechnology Co. (Guangzhou, China).

699 **scRNA-Seq data processing**

700 The Cell Ranger toolkit (version 3.1.0) provided by 10x Genomics was applied to aggregate 701 raw data, filter low-quality reads, align reads to the human reference genome (GRCh38), assign 702 cell barcodes and generate a UMI matrix. The toolkit Scanpy (version 1.9.3) ⁶⁶ was used to 703 analyze single-cell RNA sequencing (scRNA-Seq) data. Specifically, the original UMI matrix 704 was processed to filter out genes expressed in less than 10 cells and cells with less than 200 705 genes. We further quantified the number of genes and UMI counts per cell and maintained 706 thresholds for high-quality cells of 1000-50,000 UMIs, 400-6,000 genes and less than 10% 707 mitochondrial gene counts, ensuring that most heterogeneous cell types were Incorporate into 708 downstream analyses. Scrublet (version 0.2.3) 67 was then applied to each sequencing library to 709 remove potential doublets, using default parameters. The normalized expression matrix was 710 calculated from raw UMI counts normalized to total counts per cell (library size) and then scaled 711 by 1e4 and log-transformed.

712 **Dimensionality reduction and unsupervised clustering of scRNA-seq data**

713 Dimensionality reduction and unsupervised clustering were performed according to 714 standard workflows in Scanpy⁶⁶. Briefly, use highly variable genes (HVG) based on the 715 highly_variable_genes default parameters. Unwanted sources of variation, including total counts, 716 and mitochondrial gene counts were further regressed from the normalized expression matrix. 717 Primary component analysis (PCA) was performed on the variable gene matrix to reduce noise

718 and the top 50 components were used for downstream analysis. To correct for batch effects 719 across different patients, we applied BBKNN to generate a batch-balanced k-nearest neighbor 720 (KNN) map, which identifies the top neighbors of each cell in each batch individually, rather $\frac{721}{221}$ than the entire pool of cells ⁶⁷. The Leiden algorithm is then applied to such nearest neighbor 722 graphs to detect communities and find cell clusters 68 . It is worth noting that the same principal 723 components are also used for nonlinear dimensionality reduction to generate uniform 724 distributions for visualization in Uniform Manifold Approximation and Projection (UMAP). 725 After the first round of unsupervised clustering, we annotated each cell cluster according to 726 canonical immune cell markers and identified the main immune cell types, including T cells, NK 727 cells, B cells, myeloid cells, fibroblasts, endothelial cells and tumor cells. Use the 728 rank_genes_groups function with parameter method Wilcoxon to detect marker gene.

729 **TCR sequences assembly**

730 Applying the TCR sequence assembly Cell Ranger toolkit (version 3.1.0) provided by 10x

731 Genomics will perform FASTQ sequence quality filtering, sequence alignment, V(D)J assembly

732 and TCRαβ pairing. Only TCRs containing paired TRAV-CDR3-TRAJ and TRBV-CDR3-

733 TRBJ-TRBC chains were considered valid and retained for downstream analysis. Each cell is

 734 assigned a pair of α and β chains with the highest UMI count. Cells with identical TCR pairs are

735 defined as clonal and are thought to originate from a common ancestor.

736 **Calculation of Diversity Index**

737 Characterize the immune repertoire by examining diversity and clonality. Immune 738 repertoire analysis involves a variety of diversity indices, such as Chao1 index, Clone Diversity 739 Index, Richness index and Shannon index 24 .

740 **Bulk RNA-sequencing and ATAC-sequencing data processing**

31

749 (https://github.com/jsh58/ATAC-seq2)

750 **Generation of Immunosenescence gene set**

751 Our own senescence-related gene set was generated by combining genes reported to be 752 enriched in senescent immune cells in previous studies and experimentally validated in at least 753 human or mouse cells. We screened 1745 studies, but after removing studies reporting duplicates, 754 case reports, non-human genes, and non-high-throughput sequencing, a list of 6 studies was 755 developed (Senmayo⁴⁶, GSE157007²⁴, HRA000624⁶⁹, HRA000395⁷⁰, HRA000615⁷¹ and 1756 HSA000203⁷² and 1 database (https://genomics.senescence.info/cells/)). We screen immune 757 cells and compare samples from young and old people to obtain differential genes that are highly 758 expressed in the elderly, remove duplicate genes, and screen genes that appear in at least two 759 data sets. Based on the enrichment of relevant gene pathways and machines Learning method, 760 154 genes constituting the immunosenescence gene set were identified (Supplementary Table 6).

761 **GO enrichment analysis and Gene set enrichment analysis (GSEA)**

762 Using the R package ClusterProfiler (version 4.8.3), gene function annotation and GO were 763 performed on genes that were down-regulated and up-regulated in T cells and B cells in the MPR 764 and noMPR groups, as well as differential genes between macrophages and monocytes and other

765 cells. Analysis, a program that supports statistical analysis and visualization of functional 766 profiles of genes and gene clusters.

- 767 GSEA was performed by the GSEA software 768 (http://software.broadinstitute.org/gsea/index.jsp)⁷³. Gene sets used in this article were 769 c2.cp.kegg.v6.2.symbols.gmt downloaded from the Molecular Signatures Database (MSigDB, 770 http:// software.broadinstitute.org/gsea/msigdb/index.jsp).
- 771 **Gene Set Score Analysis**

772 The scoregenes function in Scanpy is used to calculate the module score of a gene 773 expression program in a single cell. First, all analyzed genes were binned according to their 774 average expression, and control genes were randomly selected from each bin. Then, the average 775 expression value of the gene set at the single-cell level minus the aggregate expression of the 776 control gene set was calculated. The gene set was obtained from the immunosenescence gene set 777 constructed by ourselves. The genes in each gene set are listed in Supplementary Table 6.

778 **Cell-cell interaction**

779 We used the CellChat package (1.6.1), which allows analysis of scRNA-Seq data. We 780 studied the interaction between immune cells (i.e. T cells and B cells) and myeloid cells (i.e. 781 macrophages and monocytes), one of which contributes ligands or receptors during the 782 interaction, using CellChat Signaling pathway networks are analyzed and visualized.

783 **Trajectory inference of immune cell subsets across tissues**

784 The status of immune cell subpopulations in the periphery and in tumors is dynamic, and 785 they may differentiate into different cell states and exert different biological functions in 786 different patients. We use the pseudo-temporal inference algorithm Monocle 2 for trajectory 787 analysis to reconstruct the cell differentiation trajectory of immune cells across tissues, reveal the

33

788 progression of cells and reconstruct the trajectory of cells progressing through biological 789 processes under study.

790 **Survival analysis**

791 Survival analysis uses TCGA and HNSCC data to evaluate the prognostic performance of 792 different immune cell populations. Gene expression data and clinical information of HNSCC 793 patients were downloaded from cBioPortal (https://www.cbioportal.org/study/clinicalData). Use 794 Cibersort and Xcell to extract T cells and B cells subtypes and group them based on the 795 expression levels of characteristic genes. Specifically, HNSCC patients were divided into four 796 groups based on the median proportion of immune cell subsets and the median mean expression 797 of a given signature gene. In the analysis of myeloid cells, a subset of cells within a single cell is 798 characterized using a set of signature genes, defined based on a combination of typical marker 799 genes for major immune cell types and cluster-specific marker genes. Specifically, for different macrophage clusters, we used the typical IGF1⁺ 800 Mφ marker genes "*CD276*", "*APOE*", "*TREM2*", 801 "*HTRA1*", "*PTGR1*", "*RBP1*", "*IGF1*", "*CDKN1A*", "*CD81*" define its signature. HNSCC 802 patients were divided into two groups based on the median of the mean expression of the given 803 signature. Survival analysis was performed using the COX proportional hazards model 804 implemented in the R package "survival".

805 **Hierarchical Clustering**

806 In the end, cell subpopulations and characteristic genes were used to construct a 807 neoadjuvant treatment model for patients before surgery, and a hierarchical clustering method 808 was used to create groups. Cophenetic distance was used to evaluate the objects in the group so 809 that they were like each other and different from objects in other groups. Verify different cell 810 subpopulations and gene signatures to evaluate the efficacy of neoadjuvant therapy in patients 811 before surgery.

812 **TNBC single cell RNA sequencing data processing**

813 TNBC single-cell RNA sequencing data comes from GSE169246. Patients who received 814 combined neoadjuvant chemotherapy and immune therapy before surgery were screened, and the 815 patients were divided into PR (response) and SD (non-response) groups based on the 816 corresponding imaging conditions. The rest of the analysis process as before, similar cell 817 subpopulations were evaluated after dimensionality reduction clustering, and senescent immune 818 cells were evaluated on the cell subpopulations. Hierarchical clustering was used to verify the 819 effect of different cell subpopulations and gene characteristics on patients receiving neoadjuvant 820 therapy before surgery to evaluate.

821 **Animal experiments.**

822 The animal experiments in this study were conducted with the approval of the Animal 823 Ethics Committee of Sun Yat-sen University and the Institutional Animal Care and Use 824 Committee at the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences 825 (CAS). For all animal experiments, mice were housed under controlled conditions of ~50% 826 humidity, ~25 °C temperature and a 12h light/dark cycle. Isoflurane was used for anaesthesia. At 827 the end of all experiments, animals were euthanized under $CO₂$ anaesthesia.

828 **4-NQO-induced mouse HNSCC model.**

829 Female C57 mice (12 months old) were housed and drinking water containing 50 mg/L 4- 830 NQO was given for 12 weeks. All diet and water were made available ad libitum. Subsequently, 831 the oral cavities of the mice were examined. 24 mice with lesions were randomly divided into 4 832 groups. Normal drinking water was given. Two days later, αPD-1 was administered 833 intraperitoneally at a dosage of 10 mg/kg. Then, mice were euthanized. Tongues were collected 834 for pathological examination and IF.

835 **Establishment of cell lines and tissue culture.**

836 Female C57 mice (6-8 weeks old, weighing 18-20 g) were obtained from Gempharmatech 837 (Guangdong, China). 4-nitroquinoline 1-oxide (4-NQO) was diluted in drinking water to a final 838 concentration of 50 mg/L for the animals, with weekly replacements. After 12 weeks, all animals 839 were returned to normal water until week 28. At week 28, animals were euthanized for tissue 840 extraction. Lesions were dissected, and cells were isolated to establish the 4MOC cell line.

⁸⁴¹**SA-**β**-gal staining**

842 Fresh tissues were fixed in 10% neutral buffered formalin (NBF) for 3–4 h and then 843 transferred to 30% sucrose overnight. Tissues were then embedded in cryo-embedding medium 844 (OCT) and cryosectioned at 5 µm for staining of SA- β -gal (pH 6.0) at 37 \Box °C for 16–24 h in SA-845 β-gal staining solution (40 mM citric acid in sodium phosphate buffer, 5 mM K₄[Fe(CN)₆]3H₂O, 5 mM K ₃[Fe(CN)₆], 150 mM sodium chloride, 2 mM magnesium chloride and 1 mg ml⁻¹ X-gal 847 dissolved in *N,N*-dimethylformamide). Slides were imaged at $20\times$ with a Panoptiq slide scanner 848 (ViewSiq).

-
-

849 **RNA isolation and qRT–PCR**

850 Tissues were collected from euthanized mice and flash-frozen in liquid nitrogen. Tissues 851 were homogenized using FastPrep-24 homogenizer (MP Biomedicals) and total RNA was 852 isolated by Trizol extraction according to manufacturer's specifications (Thermo Fisher). Total 853 RNA was quantified using a Nanodrop spectrophotometer (Thermo Fisher) and 1 μg of total 854 RNA used to generate cDNA via the Transcriptor First Strand cDNA synthesis kit (Roche) according to the manufacturer's specifications. Gene expression changes in $(Cdkn2a)$ $p16^{lnk4a}$, 856 (*Cdknla*) $p21^{Cip1}$ were quantified by qRT–PCR reactions using 20 µl reaction volumes and a 857 StepOne thermocycler (Thermo Fisher) with input of 50 ng total RNA per reaction. For each 858 sample, reactions were performed in duplicate. Data were analysed by the ΔΔCt method and 859 expression was normalized to *Gapdh*.
860 **Quantitation of 8-OHdG DNA lesions**

861 Tissues from mice were analysed for 8-OHdG levels using the ELISA kit (Abcam) 862 according to manufacturer's specifications.

863 **Immunoblotting**

864 Snap-frozen livers from mice were incubated in RIPA buffer (Thermo-Fisher) on ice for 30 865 min after being homogenized with a FastPrep-24 homogenizer. Samples were centrifuged at 866 17,000g for 15 min at 4 \degree C. Supernatant was resuspended in 2× SDS loading buffer and 50 µg 867 of total protein run on a 4–15% SDS–PAGE gel (Bio-Rad) before being transferred to 868 nitrocellulose membrane. Membranes were blocked for 1 h in 10% milk TBS-T solution at room 869 temperature before incubation in anti-γH2AX (Novus Biologicals, NB100-384, 1:2,000) and 870 anti-GAPDH (Abcam, ab8425, 1:5,000) antibody at $4\degree$ °C overnight. After washing, samples 871 were incubated in either horse anti-mouse HRP (Cell Signaling Technology, 7076S) or goat anti-872 rabbit HRP secondary antibody (Thermo-Fisher, 656120, 1:2,000) in 5% milk TBS-T solution 873 for 3 h before washing and visualization with ECL (Thermo-Fisher).

874 **TIL isolation and flow cytometry**

875 Tumors were dissected, minced, and resuspended in complete media (DMEM with 10% 876 FBS and 1% antibiotics) supplemented with Collagenase-D (1 mg/mL; Roche) and incubated at 877 37 °C for 30 min with shaking to form a single-cell suspension. Tissue suspensions were washed 878 with fresh media and passed through a 100-µm strainer. Samples were washed with PBS and 879 immediately processed for live/dead cell discrimination using BD HorizonTM Fixable Viability 880 Stain 510. Cell surface staining was done for 30 min at 4 °C with the following antibodies: CD45 881 (30-F11) (1:100), CD3 (145-2C11) (1:400), CD8a (53-6.7) (1:100), CD4 (RM4-4) (1:400), 882 NK1.1 (PK136) (1:400), CD62L (MEL-14) (1:200) and CD44 (IM7) (1:100). All flow cytometry

883 data acquisition was done using Beckman Cytexpert and analyzed using FlowJo software 884 (v10.8.1).

-
- 885 **Immunofluorescence and image quantification**

886 Briefly, tissues were harvested, fixed, and paraffin embedded. Slides were stained for P16, 887 P21, CD4, CD8a, CCR7, PAN-CK, LCK, CD62L and S100A11 antibodies (Supplementary 888 Materials). Quantification of immune infiltration was done using QuPath, an open-source 889 software for digital pathology image analysis. For the quantification, at least three regions of 890 interest (ROI) were selected for each condition and the percentage of positive cells was 891 calculated.

892 **DNA sequencing and genomic signature analysis**

893 Raw sequencing data were aligned to the mm10 reference genome using BWA. Somatic 894 mutations were identified by comparing the sequencing data from each cancer sample to the 895 sequencing data from a normal tissue derived from the tail of one of the mice (all mice were 896 genetically identical). To ensure robustness of the results, a consensus variant calling strategy 897 was leveraged in which somatic mutations were identified using three independent 898 bioinformatics tools: Strelka2, Varscan2, and GATK4 Mutect2. Somatic mutational profiles 899 were derived using the immediate sequencing context by evaluating the base 5['] and the base 3' to 900 each single point mutation.

901

902 **Data availability**

903 All data associated with this study are present in the paper or the Supplementary Materials. 904 The raw sequence data including single-cell sequencing, TCR/BCR sequencing of human, as 905 well as RNA and ATAC sequencing of CD4 naïve T cells datasets generated and analyzed

932 **Acknowledgments:** We thank all patients and their families for participation during sample 933 collection. We are grateful to the support of the Clinical Research Design Division and Clinical 934 Research Center at Sun Yat-sen Memorial Hospital, Sun Yat-sen University. The co-author Dr. 935 Soldano Ferrone sadly passed away on January 10, 2023, at the age of 82, after an 8-week-long 936 battle with COVID-19. He was the supervisor of Dr. Song Fan during Dr. Fan's post-doctoral 937 work in his lab at Massachusetts General Hospital (MGH). Due to his constantly invaluable 938 guidance and suggestions, which greatly helped improve and organize this study, all contributing 939 authors agree to keep him as a co-author of this manuscript. We thank all the members of the Fan 940 lab for valuable discussions and help with experimental techniques and analysis of the 941 manuscript. This work was supported by the Joint Funds of the National Natural Science 942 Foundation of China (U21A20381), the General Funds of the National Natural Science 943 Foundation of China (82373452), the Guangdong Natural Science Funds for Distinguished 944 Young Scholar (2022B1515020061), the Guangdong Basic and Applied Basic Research 945 Foundation (2021A1515220138), the Guangzhou Basic Research Program Jointly Funded by 946 Municipal Schools (Institutes) (202201020367), the Fundamental Research Funds for the Central 947 Universities, Sun Yat-sen University (16ykpy10), the Fundamental Research Funds for the 948 Central Universities, Sun Yat-sen University (19ykzd20), the General Funds of the National 949 Natural Science Foundation of China (32071451), the Guangdong Provincial Pearl River Talents 950 Program (2021QN02Y747), the Shenzhen Science and Technology Program 951 (RCYX20210706092100003), and by the Shenzhen Medical Research Funds grant (A2303005).

952

953 **Author contributions:** X.W., S.F., X.F., F.X., N.L., J.W. and E.D. designed the study and 954 wrote the manuscript, S.F., X.F., F.X. and X.W. supervised the study. Single-cell RNA and

9 **Fig. 1 The results of the Phase II clinical trial (OOC-001) and scRNA-Seq data indicate that** 10 **MPR patients demonstrate increased diversity in immune response-related cell subtypes** 11 **and exhibit decreased expression of senescence markers.**

3

5

7

107

Fig. 5 ATAC-Seq and RNA-Seq analyses of CD4⁺ naïve T cells provide evidence for the ¹⁰⁹**potential of** α**PD-1+DQ in the regulation of immunosenescence. a,** Pattern diagram of cell 110 sorting, as well as combined sequencing with ATAC-Seq and RNA-Seq. **b,** Heatmap illustrating 111 differences in the expression levels of T cell di-related genes among different groups. **c,** DEGs 112 (Log₂Foldchages > 0.5) of CD4 naïve T cells in tumors between α PD-1 and DQ and isotype

123

138

140 **Extended Data Fig. 1 The trial design and outcomes of OOC-001.**

141 **a**, Trial flow diagram. **b**, Representative pre- and post-treatment intraoral photographs, H&E 142 staining, and MRI images for MPR and noMPR patients. Scale bar = 50 μm. **c**, The changes and 143 proportional statistics of TNM staging after treatment for lymph nodes in different patients. **d**, 144 Scatter plot depicts the pathological response and radiographic response of the primary tumor 145 after neoadjuvant treatment in the same patient (left), and the radiographic response of the 146 primary tumor and lymph node metastasis in the same patient after neoadjuvant treatment (right). 147 **e**, Pathological response of the primary tumor in patients treated with different cycles during 148 neoadjuvant therapy (left), radiographic response of the primary tumor in patients treated with 149 different cycles during neoadjuvant therapy (middle), and all remission include primary tumor 150 and lymph node metastasis in patients treated with different cycles during neoadjuvant therapy 151 (right). **f**, The rates of MPR for patients after 2 cycles, 3 cycles, and 4 cycles of treatment, as well 152 as the rates of Grade 1-2 adverse events and Grade 3-4 adverse events. **g**, Survival curves for 153 patients in this clinical trial at the 24-month follow-up. **h**, Disease-free survival (DFS) and OS 154 curves for patients in this clinical trial at the 24-month follow-up.

155 156

157 **Extended Data Fig. 2 Dynamic characterization of TCR landscape.**

158 **a**, TCR-seq was performed on T cells from tumors (pre-treatment biopsy tumors), P0 (pre-159 treatment blood), and P1 (post-treatment blood) obtained from patients (from top to bottom, 160 patients SH1, SH2, SH3, SH4, SH5, SH6, SH7). The top 10 clonotype frequencies detected in T 161 cells that differed most in peripheral blood before and after treatment are shown in serial 162 peripheral blood (left) and tumor tissue (right). **b**, From left to right represents changes in high 163 abundance clonotypes in tumors and blood before and after patient treatment, and patients from 164 top to bottom are SH1, SH2, SH3, SH4, SH5, SH6, SH7. Each circle represents a clonotype. The 165 diameter of the circle indicates the concentration of the clonotype. Persistent clonotypes are 166 marked as bright circles, with a single color representing one clonotype. For patients with MPR, 167 the predominant high-abundance clonotype present in tumors and blood before treatment 168 remained the predominant high-abundance clonotype after treatment. **c**, Pairwise similarity 169 (Grantham distance) between the top 50 most common intratumoral TCR CDR3b clones. 170 Evaluate the similarity between the most common lengths of CDR3b amino acid sequences in 171 each patient (from top to bottom, patients SH1, SH2, SH3, SH4, SH5, SH6, SH7). Red indicates 172 the most expanded clone. **d**, Bar plot of TCR and BCR clonotypes across all T cells and B cells 173 in MPR or noMPR groups from P0, P1 and tumors. One clonotype consists strictly of one paired ¹⁷⁴α-/β-chain V(D)J TCR. **e**, Pie chart of the antigen specificity of detected TCRs when considering ¹⁷⁵α-, β-, and paired strands. CMV, cytomegalovirus; EBV, Epstein-Barr virus; InfluenzaA, 176 influenza A virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; HS, Homo 177 sapiens antigen; HIV-1, human immunodeficiency virus 1; HCV, hepatitis C virus; YFV, yellow 178 fever virus; DEV, dengue virus. **f**, Representative immunofluorescence images of senescent 179 markers P16 and P21 on paraffin sections from MPR and noMPR patients in two patient cohorts 180 (Cohort1 n=50, Cohort2 n=61).

183 **Extended Data Fig. 3 Development and validation of IAGs.**

194 **Extended Data Fig. 4 Anti-tumor reactivity and immunosenescence features of T cell**

195 **subtypes.**

196 **a**, Violin plot of expression of all T cells IAGs score in HNSCC tumors between MPR and 197 noMPR groups. Black lines with different lengths indicate which two groups were compared. 198 Wilcoxon signed-rank test. **b**, Gene Venn diagram of differential genes of T cell subtypes in 199 tumors between MPR and noMPR groups. **c**, UMAP shows the distribution of T cell and B cell 200 subtypes in TNBC. **d**, Box plot of the percentage of the T cell clusters in TNBC tumors between 201 PR and SD groups. The boxed plot on the left of each T cell cluster is the PR group, and on the 202 right is SD group. Box middle lines, median; box limits, upper and lower quartiles. Black lines 203 with different lengths indicate which two groups were compared. Wilcoxon signed-rank test. **e**, 204 Violin plot of expression of all T cells IAGs score in TNBC tumors between PR and SD groups. 205 Black lines with different lengths indicate which two groups were compared. Wilcoxon signed-206 rank test. **f**, The Ridge plot of IAGs score analysis for T cells clusters in TNBC. **g**, Dot plot of 207 intersection genes of TNBC T cell DEGs and IAGs between PR and SD groups. **h**, DEGs 208 (Log2Foldchages > 0.5) of CCR7⁺ CD4 naïve T cells and CXCL13 CD4 T helper cells between 209 MPR and noMPR enriched GO terms in tumors. Log-rank test (two-sided). *P \Box < \Box 0.05, 210 ** $P \Box \subset \Box 0.01$, *** $P \Box \subset \Box 0.001$.

213 **Extended Data Fig. 5 CD4 T cell differentiation pathway.**

223 **Extended Data Fig. 6 Immunosenescence features of B cells.**

235 **Extended Data Fig. 7 Dynamics of myeloid cell subtypes after neoadjuvant**

236 **chemoimmunotherapy.**

237 **a**, UMAP embedding myeloid cell trajectory with mapping of pseudotime. **b**, UMAP plots 238 showing the distributions myeloid cells between MPR and noMPR groups. **c**, The proportion of myeloid cells in different tissues. **d**, Gene similarity between $IGF1⁺$ M_{Φ} and myeloid cell 240 clusters from peripheral blood. **e**, UMAP showing the distribution of myeloid cell clusters (left), 241 embedding the single-cell transcriptional profiles of myeloid cell from each tissue sampled (top 242 right), and from different groups (bottom right) in TNBC. **f**, The cellular compositions of 243 myeloid cell clusters in tumors and peripheral blood between PR and SD groups in TNBC. **g**, 244 Violin plot of six key SASP expression of the IAGs score in myeloid cell clusters in tumors (left) 245 and peripheral blood (right). **h**, Violin plot of six key SASP expression of the IAGs score in 246 myeloid cell clusters in tumors (left) and peripheral blood (right) from TNBC. **i**, Low expressions of $IGF1^+$ M_{Φ} signature gene were significant associated with better OS and DFS. 248 Log-rank test (two-sided).

249

²⁵¹**Extended Data Fig. 8 The effect of Senolytics combined with** α**PD-1 on TIME of 4-NQO**

252 **mice.**

DAPI PAN-CK P21 CD62L

264
All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.10.14.24315428;](https://doi.org/10.1101/2024.10.14.24315428) this version posted October 15, 2024. The copyright holder for this preprint

²⁶⁵**Extended Data Fig. 9** α**PD-1+DQ enhanced the anti-tumor effect in breast and bladder**

266 **cancer xenograft models.**

All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.10.14.24315428;](https://doi.org/10.1101/2024.10.14.24315428) this version posted October 15, 2024. The copyright holder for this preprint

All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.10.14.24315428;](https://doi.org/10.1101/2024.10.14.24315428) this version posted October 15, 2024. The copyright holder for this preprint

276 **Extended Data Fig. 10 Transcriptomic and epigenetic dynamics of CD4 naive T cells**

²⁷⁷**following the** α**PD-1+DQ therapy.**

²⁷⁸**a,** Volcano plot of differentially expressed genes between αPD-1+DQ and Isotype groups (left), 279 α PD-1 and Isotype groups (middle), α PD-1+DO and α PD-1 groups (right). **b**, DEGs 280 (Log2Foldchanges > 0.5) of CD4 naïve T cells in tumors between α PD-1 and Isotype groups 281 enriched GO terms. **c,** Proportions of the ATAC-seq peak regions representing various genome 282 annotations identified in Isotype, αPD-1+DQ and αPD-1 groups. **d,** The heatmap of different 283 annotated genes in Isotype, αPD-1 and αPD-1+DQ groups from ATAC-seq. **e,** Venn diagram of 284 peaks of CD4 naïve T cells in Isotype, αPD-1 and αPD-1+DQ groups. **f,** ATAC-seq tracks 285 showing the representative genes chromatin accessibility in the *Lck*, *Cfd*, and *Slfn2* loci for CD4 286 naïve T cells in Isotype, αPD-1+DQ and anti-PD-1 groups. **g,** RNA-seq and ATAC-seq detected 287 GO terms that were simultaneously enriched in the α PD-1 group and Isotype group (left) and GO 288 terms that were enriched in open chromatin regions unique to the α PD-1+DO group and α PD-289 1group (right).

290